USFDA grants EIR to Dishman Pharma
Shital Jibhe / 02 Feb 2017
Dishman Pharmaceuticals and Chemicals, which specialises in manufacturing active ingredients, informed that it has received an establishment inspection report (EIR) from US food and drug administration (USFDA).
Dishman Pharmaceuticals and Chemicals, which specialises in manufacturing active ingredients, informed that it has received an establishment inspection report (EIR) from US food and drug administration (USFDA).
The company has received the EIR from USFDA for its Bavla facility in Gujarat on February 01, which was inspected by the USFDA in July, 2016. Therefore, the plants in Naroda, Bavla and Switzerland continue to remain approved by the US FDA.
The stock of the company on February 1, 2017 ended in green with the gains of 0.77 per cent. However, the sector still remains under pressure as the new elected US President Donald Trumps' agenda towards the pharma industry is not in-line with the industry estimates. However, in the last one year, the stock of the company has surged by 37.04 per cent.
The share price of Dishman Pharmaceuticals and Chemicals gained 4.5 percent intraday on Thursday.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.